



(11) **EP 1 687 329 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 84**

(51) Int Cl.:  
**C12N 15/37** <sup>(2006.01)</sup> **C12N 15/81** <sup>(2006.01)</sup>  
**A61K 39/12** <sup>(2006.01)</sup> **A61K 48/00** <sup>(2006.01)</sup>  
**C07K 14/025** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**17.03.2010 Bulletin 2010/11**

(86) International application number:  
**PCT/US2004/037372**

(45) Date of publication and mention  
of the grant of the patent:  
**23.12.2009 Bulletin 2009/52**

(87) International publication number:  
**WO 2005/047315 (26.05.2005 Gazette 2005/21)**

(21) Application number: **04810619.9**

(22) Date of filing: **10.11.2004**

(54) **OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST**  
OPTIMIERTE EXPRESSION VON HPV-58-L1 IN HEFE  
EXPRESSION OPTIMISEE DE HPV 58 L1 DANS DE LA LEVURE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR**  
Designated Extension States:  
**LT LV**

(74) Representative: **Buchan, Gavin MacNicol et al**  
**Merck Sharp & Dohme Limited**  
**European Patent Department**  
**Hertford Road**  
**Hoddesdon**  
**Hertfordshire EN11 9BU (GB)**

(30) Priority: **12.11.2003 US 519211 P**

(43) Date of publication of application:  
**09.08.2006 Bulletin 2006/32**

(73) Proprietor: **Merck Sharp & Dohme Corp.**  
**Rahway, NJ 07065 (US)**

(72) Inventors:  
• **BRYAN, Janine, T.**  
**Rahway, New Jersey 07065-0907 (US)**  
• **BROWNLOW, Michelle, K.**  
**Rahway, New Jersey 07065-0907 (US)**  
• **SCHULTZ, Loren, D.**  
**Rahway, New Jersey 07065-0907 (US)**  
• **WANG, Xin-Min**  
**Rahway, New Jersey 07065-0907 (US)**  
• **JANSEN, Kathrin, U.**  
**Rahway, New Jersey 07065-0907 (US)**

(56) References cited:  
**WO-A-01/14416 WO-A-2004/084831**

- **TOBERY T W ET AL: "Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques" VACCINE, BUTTERWORTH SCIENTIFIC, GUILDFORD, GB, vol. 21, no. 13-14, 28 March 2003 (2003-03-28), pages 1539-1547, XP004412501 ISSN: 0264-410X**
- **ZHOU JIAN ET AL: "Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 6, June 1999 (1999-06), pages 4972-4982, XP002164427 ISSN: 0022-538X**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 687 329 B8**

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• LIU W J ET AL: "Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 5-6, 12 December 2001 (2001-12-12), pages 862-869, XP004312531 ISSN: 0264-410X</li> <li>• SCHILLER J T ET AL: "PAPILLOMAVIRUS-LIKE PARTICLE VACCINES" NATIONAL CANCER INSTITUTE. MONOGRAPHS, US NATIONAL CANCER INSTITUTE, BETHESDA, MD, US, vol. 28, 2000, pages 50-54, XP008016223 ISSN: 0083-1921</li> </ul> | <ul style="list-style-type: none"> <li>• HOFMANN K J ET AL: "Sequence dertermination of human papillomavirus type 6a and assembly of virus like particles in Saccharomyces cerevisiae" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 209, 1995, pages 506-518, XP002100680 ISSN: 0042-6822</li> <li>• JANSEN K U ET AL: "Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 16, November 1995 (1995-11), pages 1509-1514, XP004057408 ISSN: 0264-410X</li> </ul> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|